Mechanism by which the lectin actinohivin blocks HIV infection of target cells

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 37, 2009, Pages 15633-15638

  Tanaka, Haruo ^a   Chiba, Harumi ^b   Inokoshi, Junji ^b   Kuno, Atsushi ^c   Sugai, Takahiro ^b   Takahashi, Atsushi ^a   Ito, Yukishige ^d   Tsunoda, Masaru ^a   Suzuki, Kaoru ^a   Takénaka, Akio ^a   Sekiguchi, Takeshi ^a   Umeyama, Hideaki ^b   Hirabayashi, Jun ^c   Omura, Satoshi ^b  

^a IWAKI MEISEI UNIVERSITY   (Japan)

^b KITASATO UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

^d RIKEN   (Japan)

Author keywords

Action mechanism; Anti HIV; Cyanovirin N; gp120; High mannose type glycan

Indexed keywords

ACTINOHIVIN; CYANOVIRIN N; GLYCAN DERIVATIVE; GLYCOPROTEIN GP 120; LECTIN; MANNOSE; MICROBICIDE; RIBONUCLEASE; SUGAR; UNCLASSIFIED DRUG;

ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CRYSTAL; DRUG MECHANISM; FEMALE; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; TARGET CELL; VIRUS TRANSMISSION;

BACTERIAL PROTEINS; BINDING SITES; CARRIER PROTEINS; CRYSTALLOGRAPHY, X-RAY; HIV ENVELOPE PROTEIN GP120; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; KINETICS; LECTINS; MANNOSE; MANNOSIDES; MODELS, MOLECULAR; PROTEIN STRUCTURE, TERTIARY;

EID: 70349456136     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0907572106     Document Type: Article

References (36)

1. Cohen J (2007) Did Merck's failed HIV vaccine cause harm? Science 318:1048-1049.
2. Grant RM, et al. (2008) Whither or wither microbicides? Science 321:532-534.
3. Clapham PR, McKnight A (2002) Cell surface receptors, virus entry and tropism of primate lentiviruses. J Gen Virol 83:1809-1829.
4. Leonard CK, et al. (1990) Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type-1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J Biol Chem 265:10373-10382. (Pubitemid 20212763)
5. Chiba H, et al. (2001) A simple screening system for anti-HIV drugs: Syncytium formation assay using T-cell line tropic and macrophage tropic HIV env expressing cell lines - establishment and validation. J Antibiot 54:818-826. (Pubitemid 33049159)
6. Chiba H, et al. (2001) Actinohivin, a novel anti-HIV protein from an actinomycete that inhibits syncytium formation: Isolation, characterization, and biological activities. Biochem Biophys Res Commun 282:595-601. (Pubitemid 32917913)
7. Inokoshi J, et al. (2001) Molecular cloning of actinohivin, a novel anti-HIV protein from an actinomycete, and its expression in Escherichia coli. Biochem Biophys Res Commun 281:1261-1265. (Pubitemid 32924555)
8. Matsumoto A, et al. (2003) Longispora albida gen nov, sp nov, a novel genus of the family Micromonosporaceae. Int J Syst Evol Microbiol 53:1553-1559. (Pubitemid 37184989)
9. Chiba H, et al. (2004) Actinohivin, a novel anti-human immunodeficiency virus protein from an actinomycete, inhibits viral entry to cells by binding high-mannose type sugar chains of gp120. Biochem Biophys Res Commun 316:203-210. (Pubitemid 38299146)
10. Takahashi A, et al. (2005) Essential regions for antiviral activities of actinohivin, a sugar-binding anti-human immunodeficiency virus protein from an actinomycete. Arch Biochem Biophys 437:233-240. (Pubitemid 40585825)
11. Balzarini J (2007) Targeting the glycans of glycoproteins:Anovel paradigm for antiviral therapy. Nat Rev Microbiol 5:583-597. (Pubitemid 47074114)
12. Balzarini J (2005) Targeting the glycans of gp120:Anovel approach at the Achilles heel of HIV. Lancet 5:726-731.
13. Boyd MR, et al. (1997) Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: Potential applications to microbicide development. Antimicrob Agents Chemother 41:1521-1530.
14. Shenoy SR, et al. (2001) Selective interactions of the human immunodeficiencyvirusinactivating protein cyanovirin-N with high-mannose oligosaccharides on gp120 and other glycoproteins. J Pharmacol Exp Ther 297:704-710.
15. Bolmstedt AJ, et al. (2001) Cyanovirin-N defines a new class of antiviral agent targeting N-linked, high-mannose glycans in an oligosaccharide-specific manner. Mol Pharmacol 59:949-954.
16. Bewley CA (2001) Solution structure of a cyanovirin-N:Man alpha 1-2Man alpha complex: Structural basis for high-affinity carbohydrate-mediated binding to gp120. Structure 9:931-940.
17. Bewley CA, Otero-Quintero S (2001) The potent anti-HIV protein cyanovirin-N contains two novel carbohydrate binding sites that selectively bind to Man(8) D1D3 and Man(9) with nanomolar affinity: Implications for binding to the HIV envelope protein gp120. J Am Chem Soc 123:3892-3902.
18. Bewley CA (2001) Rapid validation of the overall structure of an internal domainswapped mutant of the anti-HIV protein cyanovirin-N using residual dipolar couplings. J Am Chem Soc 123:1014-1015.
19. Bewley CA, Kiyonaka S, Hamachi I (2002) Site-specific discrimination by cyanovirin-N for alpha-linked trisaccharides comprising the three arms of Man(8) and Man(9).J Mol Biol 322:881-889.
20. Tsai CC, et al. (2004) Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models. AIDS Res Hum Retroviruses 20:11-18.
21. Hirabayashi J, Arata Y, Kasai K (2003) Frontal affinity chromatography as a tool for elucidation of sugar recognition properties of lectins. Methods Enzymol 362:353-368. (Pubitemid 36993059)
22. Nakamura-Tsuruta S, Uchiyama N, Hirabayashi J (2006) High-thoughtput analysis of lectin-oligosaccharide interactions by automated frontal affinity chromatography. Methods Enzymol 415:311-325. (Pubitemid 44751105)
23. SandersRW,et al. (2002) The mannose-dependent epitope for neutralizing antibody 2g12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol 76:7293-7305.
24. Scanlan CN, et al. (2002) The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2g12 recognizes a cluster of α1->2mannose residues on the outer face of gp120. J Virol 76:7306-7321.
25. Umeyama H, Iwadate M (2004) Current Protocols in Bioinformatics, ed Baxevanis AD (Wiley, Hoboken, NJ), Chap 6, Unit 5.2.
26. Fujimoto Z, et al. (2000) Crystal structure of. Streptomyces olivaceoviridis E-86 betaxylanase containing xylan-binding domain. J Mol Biol 300:575-585. (Pubitemid 30695628)
27. Shenoy SR, et al. (2002) Multisite and multivalent binding between cyanovirin-N and branched oligomannosides: Calorimetric and NMR characterization. Chem Biol 10:1109-1118.
28. Woods RJ, Pathiaseril A, Wormald MR, Edge CJ, Dwek RA (1998) The high degree of internal flexibility observed for an oligomannose oligosaccharide does not alter the overall topology of the molecule. Eur J Biochem 258:372-386. (Pubitemid 28557901)
29. Hazes B (1996) The (QXW)3 domain: A flexible lectin scaffold. Protein Sci 5:1490-1501.
30. Gilkes NR, et al. (1991) Domains in microbial β-1,4-glycanases: Sequence conservation, function, and enzyme families. Microbiol Rev 55:303-315.
31. Bewley CA (2001) Solution structure of a cyanovirin-N:Manα1- 2Manα complex: Structural basis for high-affinity carbohydrate-mediated binding to gp120. Structure 9:931-940.
32. Balzarini J, et al. (2006) Mutational pathways, resistance profile, and side effects of cyanovirin relative to human immunodeficiency virus type 1 strains with N-glycan deletions in their gp120 envelopes. J Virol 80:8411-8421. (Pubitemid 44384854)
33. Huskens D, et al. (2008) Safety concerns for the potential use of cyanovirin-N as a microbicidal anti-HIV agent. Int J Biochem Cell Biol 40:2802-2814.
34. Rutenber E, Robertus JD (1991) Structure of ricin B-chain at 2.5 resolution. Proteins 10:260-269.
35. Lee YC, Lee RT (1995) Carbohydrate-protein interactions: Basis of glycobiology. Acc Chem Res 28:321-327.
36. Balzarini J, et al. (2004) Mannose-specific plant lectins from the Amaryllidaceae family qualify as efficient microbicides for prevention of human immunodeficiency virus infection. Antimicrob Agents Chemother 48:3858-3870. (Pubitemid 39304615)